• about
  • DC IMMUNOTHERAPY
    • THE PRINCIPLE
    • ABOUT MESOPHER
    • PUBLICATIONS
  • pipeline
    • PLEURAL MESOTHELIOMA
    • PERITONEAL MESOTHELIOMA
    • PANCREATIC CANCER
  • partners & investors
  • news
  • contact
  1. Home
  2. Amphera news
  3. FDA Orphan Designation granted

FDA Orphan Designation granted

06 May 2014

On May 6, 2014 the FDA – the U.S. Food & Drug Administration – granted Amphera’s treatment of malignant mesothelioma Orphan Designation.

Previous EMA Orphan Designation granted
Next Amphera is moving to a new office
  • disclaimer
  • privacy policy

© 2019 Scicomvisuals, all rights reserved.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.